Loading organizations...
§ Private Profile · Palo Alto, CA, USA
Medical technology for upper-limb prosthetics. Develops myoelectric pattern recognition systems using machine learning for intuitive control.
Based in Chicago, Illinois, Coapt Systems develops advanced myoelectric pattern recognition systems that utilize machine learning to provide intuitive control for upper-limb prosthetics. The company's technology decodes muscle signal patterns in real time to enhance amputee functionality without requiring invasive procedures, selling its devices through licensing agreements. Operating as a bootstrapped and cash flow-positive enterprise since its first commercial sale in 2013, the firm maintained a lean team of five full-time employees and two contractors before its acquisition. Coapt Systems partners with major prosthesis manufacturers to integrate its technology, working alongside recognizable industry names such as Ottobock, Touch Bionics, Steeper, and Motion Control. In March 2025, the medical technology company was officially acquired by Hanger to operate within its products and services division. Coapt Systems was founded in 2012 by Blair Lock, Todd Kuiken, Levi Hargrove, and Jonathan Sensinger.
Coapt Systems has raised $41.0M across 3 funding rounds.
Coapt Systems has raised $41.0M in total across 3 funding rounds.
Coapt Systems has raised $41.0M in total across 3 funding rounds.
Coapt Systems's investors include Canaan Partners.
Coapt Systems has raised $41.0M across 3 funding rounds. Most recently, it raised $23.0M Series E in March 2007.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2007 | $23M Series E | — | Canaan Partners | Announced |
| Feb 1, 2003 | $12M Series C | — | Canaan Partners | Announced |
| Jan 1, 2002 | $6M Series B | — | Canaan Partners | Announced |
Coapt Systems (also referred to as Coapt, LLC or Coapt Engineering) is a Chicago-based medical technology company specializing in advanced myoelectric pattern recognition systems for upper limb prostheses. It develops the Coapt Gen2 and Complete Control systems, which act as an "intent decoder" brain for prosthetic hands, wrists, and elbows, capturing and decoding muscle signals in real-time to enable intuitive, natural control.[1][2][3] These products serve amputees and individuals with congenital limb differences, as well as clinicians fitting over 400 compatible prosthetic configurations, including those with TMR (targeted muscle reinnervation) or osseointegration; they solve the problem of cumbersome, non-intuitive prosthesis control by using machine learning for seamless personalization via a simple calibration and mobile app.[2][3] The company demonstrates growth momentum through rapid hardware iterations (e.g., 36 designs in 12 weeks via additive manufacturing), Department of Defense grants ($2.3M for VR therapy), acquisitions like Liberating Technologies, Inc. (LTI), global distribution expansion, and partnerships such as with WillowWood and Hanger Clinic.[1][6]
Coapt pioneered myoelectric pattern recognition for upper extremity prosthetics about 10 years ago (circa 2015), becoming the first company to introduce this technology for controlling prosthetic hands, wrists, and elbows.[2] Key figures include Blair Lock (featured in media like NOVA on PBS) and Todd Farrell, Ph.D., who transitioned to CEO of Liberating Technologies after Coapt's acquisition of the firm.[6] The idea emerged from academic research in human-machine interfaces, evolving from initial COMPLETE CONTROL systems using machine learning to decode muscle signals, with pivotal moments like 2018's second-generation redesign for optimized software/hardware and 2019's AI enhancements for clinicians and users.[1][5][6] Early traction included Department of Defense funding and rapid prototyping partnerships, humanizing the mission to make prosthetic movement "second nature" for users facing limb loss from injury, illness, or birth.[1][6][7]
Coapt stands out in the prosthetics market through these key strengths:
Coapt rides the wave of AI and machine learning in neuroprosthetics, transforming rigid myoelectric controls into adaptive, brain-like systems that mimic natural movement—a trend accelerated by post-WWII prosthetic evolution and modern connected health tech.[3][6][7] Timing is ideal amid rising amputation rates from trauma/war, aging populations, and DoD investments in rehab (e.g., $2.3M VR for phantom limb pain), with market forces like 3D printing enabling rapid redesigns and AI enhancing outcomes like ADLs and prosthetic usage.[1][6][7] It influences the ecosystem by setting standards for personalized control, fostering clinician tools, and expanding via acquisitions/partnerships, challenging giants like Ottobock while enabling scalable healthcare innovation in a $1M-$10M revenue niche.[4][6]
Coapt is poised for acceleration through Hanger's acquisition, LTI integration, and global distribution, potentially scaling Gen2 into full connected health platforms with VR therapy and AI analytics for better patient outcomes.[6][7] Trends like IoT-embedded liners, osseointegration adoption, and defense-funded rehab will shape its path, evolving influence from niche innovator to ecosystem leader in intuitive bionics. This builds on its core mission—making advanced prosthetics accessible and natural—positioning Coapt to redefine mobility for millions with limb differences.[2][6]